Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 5 versus DYANAVEL XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 5 versus DYANAVEL XR.
ADDERALL XR 5 vs DYANAVEL XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR 5 contains a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Dyanavel XR is a central nervous system stimulant that increases the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and increasing their release, thereby enhancing neurotransmission in the brain regions involved in attention and impulse control.
20 mg orally once daily in the morning
Initial dose: 5 mg orally once daily in the morning. Maximum dose: 20 mg once daily. May increase by 5–10 mg weekly based on tolerability and response.
None Documented
None Documented
d-Amphetamine: 10-13 hours (adults), 11-14 hours (children); l-Amphetamine: 13-15 hours (adults). The prolonged terminal half-life of the extended-release formulation supports once-daily dosing.
Mean terminal elimination half-life is approximately 8-10 hours for d-amphetamine and 12-14 hours for l-amphetamine; the extended-release formulation maintains therapeutic concentrations for 12-14 hours.
Renal (approximately 90% as unchanged drug and metabolites, with 30-40% as unchanged amphetamine), fecal (minimal, <5%)
Approximately 30-50% of a dose is excreted unchanged in urine; remainder as metabolites (primarily hippuric acid) via renal elimination. Fecal excretion is minimal.
Category C
Category C
CNS Stimulant
CNS Stimulant